Dynamic Risk Prediction in MASLD: Watch the “Ask the Author” Interview with Prof. Jérôme Boursier
Ask the author session
The Swiss NASH Foundation is pleased to highlight a transformative conversation in the field of metabolic dysfunction-associated steatotic liver disease (MASLD). In a recent edition of the “Ask the Author” series, host Prof. Jean-François Dufour sits down with Prof. Jérôme Boursier, Head of Hepatology at the University Hospital of Angers, to explore his research publication in Clinical Gastroenterology and Hepatology.
The interview dissects a major clinical challenge: moving beyond static, single-snapshot liver evaluations toward dynamic, personalized risk modeling. By capturing how non-invasive test results evolve over time, Prof. Boursier and an international collaboration of researchers have developed a model capable of calculating a patient’s individual probability of developing severe liver complications.
👉 You can watch the full interview below between Prof. Jérôme Boursier and Prof. Jean-François Dufour — don’t miss it.
1. The Clinical Need: Beyond Static Diagnostic Snapshots
For clinicians managing patients with MASLD, traditional care has relied heavily on cross-sectional evaluations—staging liver fibrosis or inflammation at a single point in time. However, as Prof. Dufour notes during the discussion, static lesion staging offers an imperfect picture of disease progression and fails to capture how a patient’s trajectory changes over years of follow-up.
Prof. Boursier explains that while non-invasive tests (NIVs) like FibroScan (vibration-controlled transient elastography) and blood-based biomarkers like the Fibrosis-4 (FIB-4) index were originally created for diagnostic staging, longitudinal research confirms they also serve as powerful prognostic markers. Single measurements alone, however, cannot easily convey a patient’s long-term trend to the treating physician. Integrating baseline parameters with subsequent longitudinal measurements allows clinicians to track disease dynamics and deliver true risk stratification.
2. Scientific Breakthrough: The VCTE-Prognosis Cohort and JLCM
To address this gap, Prof. Boursier and his co-authors evaluated data from the international VCTE-Prognosis cohort, encompassing 13,627 adult patients with MASLD. Across a median follow-up period of 4.0 years, researchers tracked repeated non-invasive test measurements alongside hard clinical outcomes, specifically liver-related events (LREs) defined as cirrhosis decompensation or hepatocellular carcinoma.
Using an advanced statistical technique known as Joint Latent Class Modeling (JLCM), the team combined longitudinal test dynamics with baseline survival factors. The model incorporates five core clinical variables:
- Age and Sex: Baseline demographic factors that adjust baseline risk trajectories.
- Liver Stiffness Trajectory: Sequential FibroScan (VCTE) measurements tracked over time.
- FIB-4 Index Dynamics: Longitudinal changes in serum biomarker scoring.
- Platelet Counts: Key hematologic indicators of portal hypertension and disease severity.
How the Model Predicts Patient Outcomes:
- Inputs: Patient age, sex, longitudinal FibroScan (liver stiffness) dynamics, FIB-4 index trajectory, and platelet counts.
- Statistical Engine: Joint Latent Class Modeling (JLCM) integrating baseline survival and biomarker trajectories.
- Personalized Output: Concrete event probabilities (ranging from 0% to 100%) for developing liver-related events at 5-year and 10-year time horizons.
Key Study Finding: The joint latent class model demonstrated superior predictive accuracy compared to traditional static measurements. In validation analyses, the model achieved an integrated area under the receiver operating characteristic curve (AUROC) that increased from 88.2% at baseline to 92.2% at the 5-year follow-up visit. Furthermore, the JLCM successfully identified 61% to 80% of patients who subsequently experienced liver-related events as high risk, significantly outperforming single-point liver stiffness measurements (39%–56%) and FIB-4 scores alone (32%–60%).
3. Practical Implications: A Cardiology-Style Paradigm Shift
A central theme of the interview is how this dynamic risk model reshapes daily patient care and physician-patient communication. Prof. Boursier draws a direct comparison to cardiovascular medicine, where clinicians do not focus solely on anatomical vessel stenosis but instead use risk equations to guide preventive therapy.
Transforming Patient Communication and Resource Allocation
Rather than explaining complex histological jargon such as MASH grades or stage-specific fibrosis lesions, physicians can discuss concrete, understandable clinical outcomes. Telling a patient their 5-year risk of liver cancer or decompensation is under 2% provides clear, actionable context.
The table below summarizes how dynamic risk modeling shifts clinical practice compared to traditional diagnostic approaches:
| Clinical Dimension | Traditional Diagnostic Approach | Dynamic JLCM Risk Model Approach |
|---|---|---|
| Primary Focus | Staging histological lesions (e.g., fibrosis stage at one visit) | Predicting hard clinical outcomes (liver cancer, decompensation) |
| Data Utilization | Single snapshot test value at presentation | Multi-visit longitudinal trajectory combining history and baseline data |
| Core Variables | Standalone FibroScan score or FIB-4 index | Combined age, sex, FibroScan trajectory, FIB-4 trajectory, and platelets |
| Patient Dialogue | Explaining complex tissue histology concepts | Sharing concrete event probabilities (0%–100%) over 5 and 10 years |
| Care Delivery | Uniform surveillance schedules for broad patient groups | Targeted surveillance for high-risk; reassurance for low-risk patients |
As Prof. Dufour emphasizes, this individualized approach offers immense reassurance to the large population of MASLD patients whose test trends remain stable and low-risk over time. Concurrently, it empowers healthcare teams to concentrate intensive monitoring and novel pharmacological treatments on the subset of high-risk individuals who need them most.
Watch the Full “Ask the Author” Video Interview
The Swiss NASH Foundation invites all hepatologists, gastroenterologists, primary care providers, and patient advocates to watch this insightful 6-minute interview. By moving from static diagnostic snapshots to dynamic prognostic modeling, clinical hepatology takes a major step toward personalized, precision care.
The Swiss NASH Foundation remains committed to bringing you the latest scientific breakthroughs, expert commentary, and educational resources in steatotic liver disease. Stay connected with our platform for future clinical updates and video features.
Thank you to our sponsors
